It has become clear that 5-amionosalicylic acid (5-ASA) is the therapeutically active moiety of sulphasalazine in the treatment of inflammatory bowel disease (IBD). Orally ingested conventional release 5-ASA tables demonstrate that the drug is rapidly and completely absorbed from the upper gastrointestinal tract.